Insider Buys 66,350 Shares of Codexis, Inc. (CDXS)
De Vre Raymond purchased 66,350 shares of Codexis, Inc. on June 17, 2026.
Key Points
- De Vre Raymond bought 66,350 shares of Codexis, Inc. on June 17, 2026, with no transaction value disclosed.
- Codexis, Inc. shares traded at $2.48, with a market cap of $233.6 million and a forward P/E ratio indicating no profitability.
- Analysts like Cantor Fitzgerald and Piper Sandler reiterated 'buy' ratings, with price targets up to $11.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, De Vre Raymond purchased 66,350 shares of Codexis, Inc. (NasdaqGS: CDXS). The transaction was not planned, and no purchase price or total value was disclosed.
Insider Buying and Selling at Codexis, Inc.
Several insiders, including Christos Richards, Stewart Parker, and David Smith, each bought 66,350 shares of Codexis on June 17, 2026. These transactions were not part of a pre-planned trading program.
Other Institutional Activity in Codexis
Aberdeen Group PLC increased its holdings by 713,870 shares, bringing its total to 8,680,368 shares, valued at about $14.15 million. Meanwhile, BlackRock, Inc. reduced its position by 366,967 shares, holding 7,028,773 shares valued at approximately $11.46 million. Millennium Management LLC added 862,938 shares, ending with 3,998,130 shares worth roughly $6.52 million.
Codexis, Inc. Stock Up 61.6%
Shares of Codexis, Inc. (NasdaqGS: CDXS) traded at $2.48. The company has a market cap of $233.6 million and a forward P/E ratio indicating it is not currently profitable. Codexis has a 52-week low of $0.96 and a high of $3.87. The stock's 50-day moving average is $2.57, and its 200-day moving average is $2.02.
$CDXS stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Codexis reported revenue of $78.09 million, with a slight growth of 1.02%. The company is not profitable, posting a net margin of -40.97% and a return on equity of -68.90%. Codexis is expected to release its next earnings report on August 12, 2026.
Analysts Set New Price Targets
On August 29, 2024, Cantor Fitzgerald reiterated its 'buy' rating for Codexis with a price target of $11. Piper Sandler also reiterated a 'buy' rating, setting a target of $10. The consensus among analysts is a 'buy' rating, with a mean price target of $6.58 based on six analyst opinions.
About Codexis, Inc.
Codexis, Inc. is a biotechnology company based in Redwood City, California. It specializes in developing enzyme-based solutions for therapeutics manufacturing using its CodeEvolver platform. The company operates in various regions, including the United States, Europe, and Asia, and partners with firms like Aldevron LLC and Pfizer Inc. Dr. Alison Moore serves as CEO, and the company employs 146 people.
Bottom Line
The insider purchase by De Vre Raymond highlights ongoing interest in Codexis, Inc. Shares remain volatile with a forward P/E suggesting no current profitability, but analyst ratings show optimism. Investors watch insider and institutional activities closely, though 13F filings are backward-looking and may not reflect current positions.
Get Codexis, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CDXS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.